About Us
Company Profile
Guangzhou Wood to Wood Health Biotechnology Co., Ltd. is an innovative enterprise specializing in the prevention, diagnosis, and innovation of allergic diseases. The technology is derived from the Guangdong Province Key Laboratory of Allergy and Immunology, and the State Key Laboratory of Respiratory Diseases. Its original technology team has been deeply engaged in this field for over 40 years, with researchers coming from the Department of Hypersensitivity of the Second Affiliated Hospital of the University of Science and Technology and the Department of Hypersensitivity of the First Affiliated Hospital of Guangzhou Medical University. The company aims to eliminate/reduce the impact of allergic diseases on the public, pioneer in prevention, provide comprehensive and precise diagnosis, enhance safe and comfortable treatment, and ultimately keep the public away from allergies.
Development Path
With the rise of global health awareness, allergic diseases have become an increasingly serious public health issue, attracting widespread attention. In this context, Guangzhou Wood to Wood Health Biotechnology Co., Ltd. emerged to dedicate itself to providing the public with innovative products for the prevention, diagnosis, and treatment of allergic diseases.
The establishment of the company originated from a profound understanding of allergic diseases and the inadequacies of existing treatment methods. The founding team, led by Academician Zhong Nanshan, brought together top experts from the Guangdong Province Key Laboratory of Allergy and Immunology, the State Key Laboratory of Respiratory Diseases, and affiliated hospitals of Guangzhou Medical University. With over 40 years of deep cultivation experience in the field of allergic diseases, they provided a solid R&D foundation for the company.
Under the strong R&D background, Guangzhou Wood to Wood Health Biotechnology Co., Ltd. continuously introduces innovative products. Immubaste® Oral Care Ointment, as one of its representatives, has been widely used in clinical practice and received high praise from patients. In addition, the company has launched a series of related products, such as nebulizers, mouthwash, and anti-allergy masks, to meet the needs of different patients.
Beyond product innovation, Guangzhou Wood to Wood Health Biotechnology Co., Ltd. also focuses on the R&D and upgrading of technology. Under the guidance of Professor He Shaoheng, a Yangtze River Scholar, and Academician Zhong Nanshan, the company's core technology team has continuously broken through technical bottlenecks and achieved several provincial and municipal scientific and technological awards. These technological achievements have not only enhanced the company's core competitiveness but also laid a solid foundation for its long-term development.
As a technology company full of vitality and creativity, Guangzhou Wood to Wood Health Biotechnology Co., Ltd. always adheres to the purpose of "eliminating/reducing the impact of allergic diseases on the public." The company not only focuses on the R&D and promotion of products but also actively participates in social welfare activities to raise public awareness and prevention of allergic diseases. Meanwhile, the company actively engages in exchanges and cooperation with domestic and international peers to jointly promote the progress and development of the allergic disease field.
Looking forward, Guangzhou Wood to Wood Health Biotechnology Co., Ltd. will continue to delve into the field of allergic diseases, constantly innovating and breaking through. The company plans to further expand the scale of its R&D team, strengthen cooperation with leading international companies, and introduce more advanced technologies and concepts. At the same time, the company will actively expand into international markets to provide better solutions for allergy sufferers worldwide.
In summary, the development history of Guangzhou Wood to Wood Health Biotechnology Co., Ltd. is an epic filled with innovation, breakthroughs, and cooperation. On the path ahead, the company will continue to adhere to its original aspirations and mission, relentlessly pursuing excellence and progress, and contributing more to human health.
Our Team
Company founder, R&D Director
Dr. Tao Ailin
Tao Ailin, Director of the Hypersensitivity (Allergy) Center, Professor at Guangzhou Medical University, doctoral supervisor, Director of the Hypersensitivity (Allergy) Center at the Second Hospital of Guangzhou Medical University, Deputy Director and academic leader of the National Clinical Key Specialty of Hypersensitivity at the same hospital. Currently, he serves as a PI at the State Key Laboratory of Respiratory Diseases, founding director of the Guangdong Key Laboratory of Allergy and Immunology, committee member of the Allergy Branch of the Chinese Medical Association, successive member of the National Transgenic Safety Evaluation Committee (fourth consecutive term), member of the Protein Allergenicity-Toxicity-Bioinformatics PATB Committee of the International Society for Health and Environmental Sciences, Vice President of the Guangdong Preventive Medicine Association, Vice Director of the Allergy Branch of the Guangdong Medical Association. He is also the Vice Director of the Clinical Immunology Branch of the Guangdong Society of Immunology, Vice Director of the Hospital Research Laboratory Construction and Management Committee of the Guangdong Hospital Association, standing committee member of the Allergy Medicine Committee of the Chinese Research Hospital Society, standing committee member and Secretary-General of the Pediatric Allergy Immunology Rheumatism Branch of the Asia Pacific Biomedical Immunology Society, and the first Executive Deputy Director of the Guangzhou Hoffman Institute of Immunology (2016-2018). In 2015, he was selected as a key medical talent in the high-level health personnel project of Guangzhou, and in 2019, he was recognized as an outstanding expert in Guangzhou. He is an editorial board member of the SCI journal Journal of Immunotherapy Applications and the English journal World Journal of Respirology, as well as a senior reviewer for multiple SCI journals. He developed the allergen family characteristic peptide AFFP algorithm for allergen analysis, leading to the creation of the allergen sequence discrimination software SORTALLER, which has the highest accuracy and is continuously used by researchers in more than 30 countries worldwide, including the USA, UK, Germany, Japan, and Canada. He has proposed concepts such as major representative allergens, antigenic attenuation, and multi-targeted allergens, as well as the antigen balance stimulation hypothesis, delving into the theory and practice of prevention of allergic diseases. He is advancing translational research on the prevention, diagnosis, and treatment of allergic diseases, with the translational achievement Immubaste® Oral Care Ointment already being widely used in clinical practice. He has published over 60 SCI papers and received the Second Prize of Guangdong Science and Technology Award, the First Prize of Guangdong Preventive Medicine Science and Technology, and the First Prize of Guangzhou Science and Technology Award (all ranked first).
One of the company’s technology originators
Wei Lai
Professor Wei Lai, a professor at Guangzhou Medical University, formerly a professor at the Zhongshan Ophthalmic Center of Sun Yat-sen University and the deputy director of the Ophthalmic Research Institute; a doctoral supervisor; and a national distinguished expert (youth). Professor Wei Lai has published 122 papers in academic journals including Cell, Immunity, Cancer Cell, Cell Res, Cell Discov, Prog Retin Eye Res, Nature, Nat Med, Nat Immunol, with a total IF exceeding 1890, total citations over 13,000, filed for more than 110 invention patents, nearly 70 international patents, and has been awarded 19 national and local funds totaling nearly 60 million. He currently serves as the Deputy Director of the Ophthalmic Traditional Chinese Medicine Technology Committee of the China Association of Chinese Medicine, a member of the Eye Immunology Group of the Ophthalmology Branch of the Chinese Medical Association, a member of the Eye Immunology Group of the Ophthalmology Branch of the Chinese Medical Doctor Association, and a reviewer for multiple domestic (Natural Fund) and international funds (Human Frontier Science Program; Dutch Arthritis Foundation; Fight for Sight). Professor Wei Lai focuses on the interaction between host-microbe in human diseases. Using cellular and molecular immunology, computational biology methods, combined with high-throughput sequencing technology and model animal tools, he explores the etiology, diagnosis, and personalized treatment methods of infectious immune diseases through various immunomics studies such as metagenomics, epigenomics, and metabolomics. In recent years, Wei Lai has also led the research and development and productization of several ophthalmic First-in-Class innovative drugs.
One of the company’s technology originators
He Yunheng
A renowned medical expert and educator, currently serving as a "Yangtze River Scholar" Distinguished Professor appointed by the Ministry of Education, an expert receiving a special government allowance from the State Council, the Chairman of the Academic Committee of Jinzhou Medical University, the Vice Chairman of the Degree Committee of Jinzhou Medical University, the Executive Dean of the Institute of Translational Medicine at Jinzhou Medical University, the Vice President of the First Affiliated Hospital of Jinzhou Medical University, and the Director of the Center for Allergy and Clinical Immunology Research at Jinzhou Medical University. Professor He Shaoheng is also one of the first batch of high-level "Outstanding Talents" in Shenyang in 2017.
Professor He Shaoheng has a rich and distinguished educational background. He studied clinical medicine at Harbin Medical University from 1978 to 1982, after which he graduated with a Bachelor of Medicine degree. Subsequently, he went on to conduct visiting scholar research at Central State University in Oklahoma, USA, in 1985, and at the School of Medicine, University of Southampton, UK, in 1990. From 1993 to 1996, he pursued a PhD in Immunopharmacology at the School of Medicine, University of Southampton, and was awarded his doctorate.
Professor He Shaoheng's career has spanned several important stages. He served as a resident and attending physician at the Second Affiliated Hospital of Harbin Medical University and the Central Hospital affiliated with Shenyang Medical College, gaining a wealth of clinical experience. At the School of Medicine, University of Southampton, he held various positions such as researcher, postdoctoral research fellow, master's supervisor, senior researcher, and doctoral supervisor, and led the leadership team of the Respiratory Molecular and Biology division in collaboration with the world-renowned Professor S.T.Holgate. He has also served as a "Yangtze River Scholar" Distinguished Professor and doctoral supervisor at Shantou University Medical College, as well as the Director of the Clinical Experimental Research Center, doctoral supervisor, and Distinguished Professor at the First Affiliated Hospital of Nanjing Medical University.
Professor He Shaoheng's expertise spans a wide range of medical fields, including allergology, clinical immunology, and immunopharmacology. He has achieved significant research results and academic contributions in these areas, making important contributions to the development of the medical profession.
Deputy Director of Technology
Yan Jie
Professor at the Second Affiliated Hospital of Guangzhou Medical University, recognized as a "Yangcheng Scholar" in Guangzhou, a youth member of the Allergy Branch of the Chinese Medical Association, a member of the Allergy Branch of the Guangdong Medical Association, and a standing committee member of the Allergy Disease Prevention and Control Professional Committee of the Guangdong Preventive Medicine Association. The research focuses on the molecular regulation mechanisms of cell programmed death and inflammation. Long engaged in the study of the pathogenesis of inflammatory-related diseases such as allergies, asthma, fibrosis, and the molecular mechanisms of cell signaling transduction networks, particularly in the regulatory molecular mechanisms of cell programmed death and tissue immune response regulation. This includes pioneering the molecular pathway by which cytotoxic TNFα regulates cell apoptosis and conducting preliminary explorations on the application of inhibitors of related regulatory molecules in the clinical treatment and translation of inflammatory-related diseases. Related research findings have been published in high-impact journals such as Cell, Cell Research, and Allergy.
R&D Consultant
Zhong Nanshan
Zhong Nanshan, an internationally renowned expert in respiratory medicine, is the Director of the Guangzhou Laboratory, Director of the National Clinical Research Center for Respiratory Diseases at the First Affiliated Hospital of Guangzhou Medical University, an Academician of the Chinese Academy of Engineering, and a recipient of the Medal of the Republic.
Transformation of Innovation Achievements
Innovation Research Institute
The Innovation Research Institute is the core of our organization, dedicated to pioneering cutting-edge research in the field of hypersensitivity. Our institute gathers top scientists and researchers who possess not only profound academic backgrounds but also extensive practical experience. Through close collaboration with well-known academic institutions both domestically and internationally, our institute has achieved significant accomplishments in technological innovation and scientific discovery. Our goal is to continuously explore and develop new scientific methods and technologies to address the challenges posed by allergic diseases and improve the quality of life for people. The Innovation Research Institute serves not only as a cradle for scientific exploration but also as a concrete manifestation of our commitment to improving human health for society.
R&D Achievements
Our R&D achievements are the best proof of our commitment to innovation and perseverance. In 2022, we were honored with the First Prize in Science and Technology by the Guangdong Preventive Medicine Association, a high recognition of our R&D team's hard work and innovative results. This achievement represents our leading position in the research field of allergic diseases and is also an affirmation of our R&D team's professional capabilities and innovative spirit. Our R&D outcomes not only enhance our company's core competitiveness but also contribute to the advancement of the entire healthcare industry. We will continue to dedicate ourselves to researching and developing more innovative medical solutions, bringing hope and improvement to patients with allergic diseases.
National patented technology
Our company has continuously leading original technologies, and these technologies have obtained a number of national patents. Our core technology platform leads the world in its innovation and efficiency. The development of these technologies is based on in-depth scientific research and rigorous experimental verification, ensuring the high quality standards of our products and services. The core advantage of having these patented technologies allows us to occupy a prominent position in the allergy prevention and treatment market and provide our customers with state-of-the-art solutions. Our ongoing pursuit of innovation and the continuous development of patented technologies are not only the cornerstone of our business success, but also a reflection of our commitment to society and the health of our customers.
National invention patent number: ZL200610034964.3, ZL201110302532.7